Gradual weight loss typically occurs over time when GLP-1 injections are combined with healthy eating and consistent physical activity
Clinical trial subgroup analyses consistently show that participants with a BMI of 35 or higher lose a larger percentage of body weight than those with lower BMIs
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control, facilitate clinically meaningful weight loss, improve survival, and reduce the risk of renal failure and major adverse cardiovascular events
At Set Point Medical Weight Loss Clinic, we are committed to providing comprehensive healthcare that aims to not only treat but also prevent chronic diseases
Landmark trials demonstrated that GLP-1 agonists can produce 10-22% body weight reduction over 68 weeks, depending on the specific agent and patient population
The newly released clinical trial data comes on the heels of another study published in July that found Mounjaro, which also has tirzepatide as its main active ingredient, was more effective for weight loss than Ozempic, whose main active ingredient is semaglutide
